RT Journal Article
SR Electronic
T1 Radiopharmacy: Delayed Skin Rash Following Administration of Technetium-99m Diphosphonate: A Case Report
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 184
OP 185
VO 17
IS 4
A1 Hart, Blaine
A1 Sorenson, James F.
A1 Eisenberg, Brian
A1 Glactz, George
A1 Owens, Deborah
A1 Hladik, William B.
A1 Curry, Mary C.
YR 1989
UL http://tech.snmjournals.org/content/17/4/184.abstract
AB We report a case of a 48-yr-old woman who developed a delayed skin rash following intravenous (i.v.) administration of technetium-99m hydroxymethylene diphosphonate (99mTc-HDP). The rash was characterized by skin biopsy, and it was concluded that the reaction was due to the diphosphonate compound. The rash resolved spontaneously without treatment. With most 99mTc-based agents, adverse reactions are considered rare and are usually allergic in nature, but the delayed nature of this reaction is more common with diphosphonate compounds than with other radiopharmaceuticals. If a repeat examination is required, alternative agents (such as 99mTc-pyrophosphate) or any other diagnostic modality (magnetic resonance imaging) may be considered. An intradermal skin test may be helpful to determine the safest alternative bone agent.